Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,719
Out of 5,131 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.34 | +1,765.67% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $2.98 | +235.57% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $5.81 | +37.69% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $33.05 | +154.16% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $9.25 | +332.43% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $7.58 | +45.12% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $1.44 | +1,358.33% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $6.78 | +13,174.34% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.34
Upside: +1,765.67%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $2.98
Upside: +235.57%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $5.81
Upside: +37.69%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $33.05
Upside: +154.16%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $9.25
Upside: +332.43%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $7.58
Upside: +45.12%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $1.44
Upside: +1,358.33%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $6.78
Upside: +13,174.34%